Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31 | $1 | $0 | $0 |
| % Growth | 2,481.5% | 766.2% | -53.4% | – |
| Cost of Goods Sold | $1 | $59 | $53 | $55 |
| Gross Profit | $30 | -$58 | -$52 | -$55 |
| % Margin | 98% | -4,798% | -37,681.3% | -18,371.8% |
| R&D Expenses | $84 | $59 | $53 | $55 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $132 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | $55 | -$4 | -$23 |
| Operating Expenses | $228 | $114 | $48 | $32 |
| Operating Income | -$197 | -$172 | -$101 | -$87 |
| % Margin | -634.2% | -14,265% | -72,489.2% | -29,224.8% |
| Other Income/Exp. Net | -$3 | -$5 | -$1 | -$1 |
| Pre-Tax Income | -$200 | -$177 | -$102 | -$88 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$200 | -$177 | -$102 | -$88 |
| % Margin | -644.8% | -14,710.9% | -73,341% | -29,449% |
| EPS | -0.63 | -0.8 | -0.62 | -0.61 |
| % Growth | 21.3% | -29% | -1.6% | – |
| EPS Diluted | -0.63 | -0.8 | -0.62 | -0.61 |
| Weighted Avg Shares Out | 320 | 221 | 166 | 146 |
| Weighted Avg Shares Out Dil | 320 | 221 | 166 | 146 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $8 | $2 | $0 |
| Interest Expense | $16 | $13 | $3 | $1 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$184 | -$170 | -$100 | -$87 |
| % Margin | -592.9% | -14,099.3% | -71,966.2% | -29,126.8% |